Commentary

On a recent visit to Israel, columnist Michael Rosen not only experienced a booming biotechnology sector, he saw one that is willing to partner with its American biotech counterparts. In this edition of Yer Biotech Blues, Rosen witnessed some amazing technology coming from a country...

Gundersen Clinic may have struck a blow for businesses across Wisconsin by defeating the Department of Revenue in a dispute over whether certain computerized equipment is exempt from the property tax. In this Guest Column from attorneys at the law firm Foley and Lardner, taxpayers...

Data center network technologies are an overlooked way to cut IT costs, and the options are many, according to WTN guest columnist Mark Bolsoni of Forsythe Technology. As Bolsoni explains, network and IP-based storage and server switching technologies can transform an under-performing data center into...

In the scientific debate over what makes the world go round, DNA or proteins, Dr. Ogan Gurel is hardly a fence sitter. In this edition of MedTech Futures, Gurel identifies proteins as more than a dutiful workhorse, but the substance that nearly all drugs act...

Perhaps nothing illustrates the distinction between invention and innovation more than the Italian experience, or lack thereof, with technology transfer, according to columnist Ogan Gurel. In this edition of MedTech Futures, Gurel explains what can happen to inventive societies that lack an innovative process. Fortunately...

Mediocre therapeutic results against a cancer that no other therapy has shown much success against does not mean that RNase-based therapies, such as the one being developed by Madison's Quintessence Biosciences, will not be effective against other types of cancers. In this edition of Biotech...

As your technology business heads toward an initial public offering or a merger, the task of financial planning with stock options starts with leveraging the value of those options to the highest level, according to columnist and attorney Sverre Roang. In this WTN Guest Column,...

The global medical device industry is even more robust than big pharma but there is a real synergy developing between the two that is important to the Midwestern states that boast of a strong medical device industry, notes columnist Michael Rosen. In this edition of...

Wisconsin's entrepreneurial climate is strengthened by individual quality and by an increasing number of new start-ups, according to columnist Tom Still. In this edition of Inside Wisconsin, Still touts encouraging entrepreneurial news from the likes of the Ewing Marion Kauffman Foundation, but he writes that...